CHMP recommend licence extension for darunavir (Prezista)

The CHMP have recommended that darunavir, co-administered with cobicistat can be licensed, as part of combination therapy for treatment HIV 1 infection in adolescents aged 12 years and older, weighing at least 40 kg.

European Medicines Agency